Inactive Instrument

Other languages Alexion Pharmaceuticals, Inc.

Equities

ALXN

US0153511094

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

Alexion Pharmaceuticals, Inc.'s VOYDEYA Receives Approval in US Add-On Therapy to Ravulizumab or Eculizumab for Treatment of Extravascular Hemolysis in Adults with the Rare Disease PNH	Apr. 01
Alexion Announces Long-Term Alpha Phase III Trial Data Shows Danicopan as Add-On to Standard of Care C5 Inhibitor Therapy ULTOMIRIS	Dec. 10
Alexion Pharmaceuticals, Inc. completed the acquisition of Assets of early-stage rare disease gene therapy portfolio of Pfizer Inc..	23-09-18
Verge Genomics Announces Artificial Intelligence-Enabled Drug Discovery Collaboration with Alexion for Rare Neurodegenerative and Neuromuscular Diseases	23-09-08
Astrazeneca continue à muscler son portefeuille de médicaments	23-06-05
JCR Pharmaceuticals Co., Ltd. Announces Research Collaboration, Option and License Agreement with Alexion to Develop a Therapy Using J-Brain CargoR for Neurodegenerative Disease	23-03-30
AstraZeneca: embellie en 2022 mais déclin attendu des médicaments anti-Covid	23-02-09
AstraZeneca: embellie des résultats 2022	23-02-09
Alexion Pharmaceuticals, Inc. completed the acquisition of LogicBio Therapeutics, Inc. from a group of shareholders.	22-11-14
Alexion Pharmaceuticals, Inc. Aims to Advance Nmosd Treatment Landscape with Exceptional Ultomiris® (Ravulizumab-Cwvz) Efficacy Data At Ectrims 2022	22-10-12
Alexion Pharmaceuticals, Inc Announces Danicopan Add-On to Ultomiris (Ravulizumab-Cwvz) or Soliris Met Primary Endpoint in Alpha Phase III Trial for Patients with Paroxysmal Nocturnal Hemoglobinuria Who Experience Clinically Significant Extravascular Hemolysis	22-09-16
Astrazeneca: bénéfice lesté de charges exceptionnelles	22-04-29
Astrazeneca: bénéfice lesté de charges exceptionnelles début 2022	22-04-29
Alexion, Astrazeneca's Rare Disease Group and Neurimmune Closes Deal for Commercializing Ni006	22-03-01
Astrazeneca : les recettes liées au Covid vont reculer après une année "record"	22-02-10
Astrazeneca: le rachat d'Actelion a étouffé la rentabilité en 2021	22-02-10
Alexion Enters into an Exclusive Global Collaboration and Licence Agreement with Neurimmune AG	22-01-07
Astrazeneca tombe dans le rouge au 3e timestre, malgré le vaccin	21-11-12
AstraZeneca : to Mandate COVID-19 Shots for US Staff	21-08-30
AstraZeneca : Rare Disease Drug Improves Copper Mobilization in Late-Stage Study	21-08-26

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Alexion Pharmaceuticals, Inc.

Equities

ALXN

US0153511094

Other languages

Filters